| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 1/200-1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PTH1R; PTHR; PTHR1; Parathyroid hormone/parathyroid hormone-related peptide receptor; PTH/PTHrP type I receptor; PTH/PTHr receptor; Parathyroid hormone 1 receptor; PTH1 receptor |
| Entrez GeneID | 5745; |
| WB Predicted band size | 52kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from the Internal region of human PTH/PTHrP-R. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于PTH/PTHrP受体(PTH1R)抗体的代表性文献，涵盖抗体应用、机制及疾病关联研究：
---
1. **文献名称**：*Monoclonal Antibodies Against the PTH/PTHrP Receptor Block PTHrP-Induced Hypercalcemia In Vivo*
**作者**：J. Schlüter et al.
**摘要**：该研究开发了针对PTH1R胞外域的单克隆抗体，并在动物模型中验证其抑制PTHrP介导的高钙血症的效果。抗体通过阻断配体-受体结合，显著降低血钙水平，为肿瘤相关高钙血症的治疗提供了潜在策略。
---
2. **文献名称**：*Structural Basis of Parathyroid Hormone Receptor 1 Activation by Antibody-Derived Agonists*
**作者**：H. Zhang et al.
**摘要**：通过冷冻电镜技术解析了PTH1R与特定激动型抗体复合物的三维结构，揭示抗体如何模拟PTH/PTHrP的构象变化激活受体下游信号，为设计靶向GPCR的抗体药物提供了结构学依据。
---
3. **文献名称**：*Autoantibodies to the PTH/PTHrP Receptor in Hypoparathyroidism*
**作者**：M. Kifor et al.
**摘要**：首次在特发性甲状旁腺功能减退症患者血清中发现针对PTH1R的自身抗体，证实这些抗体可抑制PTH信号传导，导致低钙血症，揭示了自身免疫性疾病中受体抗体的病理作用。
---
如需更详细文献信息或扩展研究方向(如抗体在骨代谢疾病中的应用)，可进一步补充说明。
**Background of PTH/PTHrP-R Antibodies**
Parathyroid hormone (PTH) and PTH-related peptide (PTHrP) share a common receptor, the PTH/PTHrP receptor (PTH1R), a class B G protein-coupled receptor critical for regulating calcium homeostasis and bone metabolism. PTH, produced by the parathyroid glands, maintains serum calcium levels by acting on bones and kidneys. PTHrP, initially identified in malignancies causing hypercalcemia, plays broader roles in development, cellular proliferation, and tissue differentiation.
Antibodies targeting PTH/PTHrP-R are essential tools for studying receptor localization, expression, and signaling pathways. They help elucidate mechanisms in disorders like hyperparathyroidism, hypoparathyroidism, and PTHrP-driven tumor-induced hypercalcemia. In research, these antibodies enable detection of receptor distribution in tissues (e.g., kidney, bone, cartilage) and investigation of ligand-receptor interactions. Clinically, they contribute to diagnosing conditions linked to receptor dysfunction or autoantibodies, such as in rare autoimmune diseases.
The development of PTH/PTHrP-R antibodies has advanced understanding of receptor structure-function relationships, including ligand binding domains and activation mechanisms. Their applications extend to drug discovery, particularly for therapies targeting bone diseases (e.g., osteoporosis) or cancers overexpressing PTHrP. However, challenges remain in ensuring antibody specificity, given the receptor’s structural complexity and homology with related proteins. Ongoing research aims to refine these reagents for both diagnostic and therapeutic innovations.
×
